Drug Profile
SGN CD352A
Alternative Names: SGN-CD352ALatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Seattle Genetics
- Developer Ligand Pharmaceuticals; Seagen
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA cross linking agents; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma